Finance

Lists
Why is AMRX up 3.55%?
Dive Deeper
AMRX:NASDAQ
Amneal Pharmaceuticals Inc
$20.14
+3.55%
(+0.69) 1D
$20.14
0.00% (0.00)
After hours
Closed: Nov 6, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AMRX...
Open
$19.45
High
$20.43
Low
$19.30
Mkt. cap
7.01B
Avg. vol.
4.13M
Volume
4.73M
P/E ratio
49.45
52-wk high
$21.68
52-wk low
$11.29
EPS
$0.41
Beta
1.24
Shares outstanding
348.30M
No. of employees
9K
Open
$19.45
High
$20.43
Low
$19.30
Mkt. cap
7.01B
Avg. vol.
4.13M
Volume
4.73M
P/E ratio
49.45
52-wk high
$21.68
52-wk low
$11.29
EPS
$0.41
Beta
1.24
Shares outstanding
348.30M
No. of employees
9K
News stories
From web sources and news partners
Profile
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States. Wikipedia
About Amneal Pharmaceuticals Inc
CEOChintu Patel | Chirag Patel
Employees8.7K
Founded2002
HeadquartersBridgewater, New Jersey, United States
SectorHealth Care
IndustryPharmaceutical industry
Websiteamneal.com
Analyst ratings
Based on 6 analysts giving stock ratings to AMRX in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for AMRX in the last 3 months.
Highest
Current $20.14
$28.00 (+39.03%)
Average
$24.83 (+23.29%)
Lowest
$20.00 (-0.70%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ashwani Verma
UBS
Buy
Maintained
$28.00
+39%
11/06/2026
Daniel Clark
Leerink Partners
Buy
Maintained
$25.00
+24.1%
11/05/2026
Chris Schott
J.P. Morgan
Buy
Maintained
$25.00
+24.1%
11/04/2026
Unknown Analyst
Oppenheimer
Buy
Maintained
$27.00
+34.1%
11/03/2026
Matthew Dellatorre
Goldman Sachs
Buy
Maintained
$24.00
+19.2%
10/29/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$24.00
+19.2%
10/29/2026
Les Sulewski
Oppenheimer
Buy
Initiated
$27.00
+34.1%
09/23/2026
Glen Santangelo
Barclays
Buy
Reiterated
$20.00
-0.7%
09/21/2026
David Amsellem
Piper Sandler
Buy
Reiterated
$17.00
-15.6%
07/20/2026
Last report
Nov 3, 2026
Fiscal period
Q3 2026
$0.26 / $0.24
+9.52%beat
Revenue / Est. (USD)
862.68M / 817.86M
+5.48%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
814.32M
722.52M
796.20M
862.68M
Cost of goods sold
518.54M
403.95M
463.78M
528.81M
Cost of revenue
518.54M
403.95M
463.78M
528.81M
Research and development expenses
34.79M
38.38M
39.02M
54.57M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
146.48M
138.86M
148.72M
139.24M
Operating expense
181.28M
177.18M
186.44M
193.19M
Total operating expenses
699.82M
581.13M
650.22M
722.00M
Operating income
114.50M
141.39M
145.98M
140.68M
Other non operating income
876.00K
3.08M
-1.79M
-12.51M
EBT including unusual items
55.24M
80.18M
70.99M
15.06M
EBT excluding unusual items
57.70M
83.31M
87.20M
66.08M
Income tax expense
5.66M
2.18M
1.38M
2.75M
Effective tax rate
10.25%
2.71%
1.94%
18.27%
Other operating expenses
-1.00K
-64.00K
-1.30M
-631.00K
Net income
35.08M
62.26M
57.66M
-21.70M
Net profit margin
4.31%
8.62%
7.24%
-2.51%
Earnings per share
0.21
0.27
0.30
0.26
Interest and investment income
-
-
-
-
Interest expense
-56.24M
-53.36M
-55.04M
-58.91M
Net interest expenses
-56.24M
-53.36M
-55.04M
-58.91M
Depreciation and amortization charges
-
-
-
-
EBITDA
163.73M
184.58M
193.78M
193.94M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps